RE:RE:ASCO relevanceI am the same Geneman as per the old Yahoo ONCY and ONCY v2. Have continued to hold shares but lightened up when the response to IND213 was yet another small Ph II confirmation trial. Years have passed and here we are. I bought the original IPO at CAN$0.85 - after a 9:1 reverse split, translates to $7.50 per original share!! Like most people, underwater. I have endured the RAS story; Brad Thompson, Head and Neck results; hype of the Glioblastoma stories, the Pancreatic trials disasters, intra-tumoral injections, animal studies, and many more dead ends.
The current ONCY "Holy Grail" is the use of Pela as an adjuvant or neoadjuvant that enhances immune responses. Most cancers are "cold" with minimal immune recognition and patients with these tumors cannot experience the remarkable responses patients with "hot" tumors experience with immunotherapeutics. If Pela can convert a "cold" tumor to "hot" (increase PD-L1, PD1, CTLA4..... expression) or alter the tumor microenvironment to an inflammatory phenotype, immunotherapy can be a novel option. ER+ breast cancers are typically very "cold" and patients are not offered immunotherapy. Earlier ONCY studies and, more recently, AWARE-1, Pela treatment showed a remarkable upregulation of immune expression and T-cell infiltration and provided a benchmark as a proof-of-principle for ER+ breast cancer. IND213 and BRACELET are aimed at a clinical correlation of the observed Pela intratumoral effect in ER+ breast cancers.
In the US and Canada, there are about 300,000 incident invasive breast cancers per year and 250,000 of these will be ER+. All of Europe would experience the same number; Asia would experience more. If Pela converts cold cancers to hot and improves survival after immunotherapy, the story is done and the share price will take care of itself. This is a multi-billion $$ indication but many hurdles remain.
The ASCO results will give us more detailed updated information about this current shot-on-net for Pela treatment. We have been down this road many times. This 1st line breast cancer treatment indication is massive so the ONCY investment is again worth some careful attention. Maybe we can induce some of the ONCY investors to come out of the weeds and add to a sensible discussion.